| Unconstrained genome targeting with near-PAMless engineered CRISPR-Cas9 variants RT Walton, KA Christie, MN Whittaker, BP Kleinstiver Science 368 (6488), 290-296, 2020 | 1056 | 2020 |
| Astrocytic interleukin-3 programs microglia and limits Alzheimer’s disease CS McAlpine, J Park, A Griciuc, E Kim, SH Choi, Y Iwamoto, MG Kiss, ... Nature 595 (7869), 701-706, 2021 | 253 | 2021 |
| Broad-spectrum anti-CRISPR proteins facilitate horizontal gene transfer C Mahendra, KA Christie, BA Osuna, R Pinilla-Redondo, BP Kleinstiver, ... Nature microbiology 5 (4), 620-629, 2020 | 106 | 2020 |
| Towards personalised allele-specific CRISPR gene editing to treat autosomal dominant disorders KA Christie, DG Courtney, LA DeDionisio, CC Shern, S De Majumdar, ... Scientific reports 7 (1), 16174, 2017 | 87 | 2017 |
| Listeria phages induce Cas9 degradation to protect lysogenic genomes BA Osuna, S Karambelkar, C Mahendra, KA Christie, B Garcia, ... Cell host & microbe 28 (1), 31-40. e9, 2020 | 79 | 2020 |
| NNT mediates redox-dependent pigmentation via a UVB-and MITF-independent mechanism J Allouche, I Rachmin, K Adhikari, LM Pardo, JH Lee, AM McConnell, ... Cell 184 (16), 4268-4283. e20, 2021 | 55 | 2021 |
| Precise DNA cleavage using CRISPR-SpRYgests KA Christie, JA Guo, RA Silverstein, RM Doll, M Mabuchi, HE Stutzman, ... Nature biotechnology 41 (3), 409-416, 2023 | 42 | 2023 |
| Effective in vivo topical delivery of siRNA and gene silencing in intact corneal epithelium using a modified cell-penetrating peptide D Schiroli, MJ Gómara, E Maurizi, SD Atkinson, L Mairs, KA Christie, ... Molecular Therapy-Nucleic Acids 17, 891-906, 2019 | 42 | 2019 |
| Personalised genome editing–the future for corneal dystrophies CBT Moore, KA Christie, J Marshall, MA Nesbit Progress in Retinal and Eye Research 65, 147-165, 2018 | 41 | 2018 |
| Evaluation of TGFBI corneal dystrophy and molecular diagnostic testing C Chao-Shern, LA DeDionisio, JH Jang, CC Chan, V Thompson, ... Eye 33 (6), 874-881, 2019 | 32 | 2019 |
| Interleukin-3 coordinates glial-peripheral immune crosstalk to incite multiple sclerosis MG Kiss, JE Mindur, AG Yates, D Lee, JF Fullard, A Anzai, WC Poller, ... Immunity 56 (7), 1502-1514. e8, 2023 | 31 | 2023 |
| Capsid engineering overcomes barriers toward adeno-associated virus vector-mediated transduction of endothelial cells L Zhang, A Rossi, L Lange, N Meumann, U Koitzsch, K Christie, ... Human gene therapy 30 (10), 1284-1296, 2019 | 30 | 2019 |
| CRISPR/Cas9 gene editing demonstrates metabolic importance of GPR55 in the modulation of GIP release and pancreatic beta cell function AG McCloskey, MG Miskelly, CBT Moore, MA Nesbit, KA Christie, ... Peptides 125, 170251, 2020 | 21 | 2020 |
| Mutation-independent allele-specific editing by CRISPR-Cas9, a novel approach to treat autosomal dominant disease KA Christie, LJ Robertson, C Conway, K Blighe, LA DeDionisio, ... Molecular Therapy 28 (8), 1846-1857, 2020 | 20 | 2020 |
| Gene editing in the context of an increasingly complex genome K Blighe, L DeDionisio, KA Christie, B Chawes, S Shareef, ... BMC genomics 19, 1-20, 2018 | 18 | 2018 |
| Base editing as a genetic treatment for spinal muscular atrophy CRR Alves, LL Ha, R Yaworski, CR Lazzarotto, KA Christie, A Reilly, ... bioRxiv, 2023 | 16 | 2023 |
| Optimization of base editors for the functional correction of SMN2 as a treatment for spinal muscular atrophy CRR Alves, LL Ha, R Yaworski, ER Sutton, CR Lazzarotto, KA Christie, ... Nature biomedical engineering 8 (2), 118-131, 2024 | 13 | 2024 |
| Making the cut with PAMless CRISPR-Cas enzymes KA Christie, BP Kleinstiver Trends in Genetics 37 (12), 1053-1055, 2021 | 6 | 2021 |
| Protein Analysis of the TGFBIR124H Mouse Model Gives Insight into Phenotype Development of Granular Corneal Dystrophy MV Lukassen, ET Poulsen, J Donaghy, EH Mogensen, KA Christie, ... PROTEOMICS–Clinical Applications 14 (6), 1900072, 2020 | 2 | 2020 |
| Crispr/cas9 systems, and methods of use thereof T Moore, A Nesbit, K Christie US Patent App. 17/187,666, 2021 | 1 | 2021 |
